Human arylamine N-acetyltransferase 1: A drug-metabolizing enzyme and a drug target?

Current Drug Targets

Volumn 11, Issue 6, 2010, Pages 759-766

  Rodrigues Lima, Fernando ^a   Dairou, Julien ^a   Busi, Florent ^a   Dupret, Jean Marie ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINOPHENYL)BENZOTHIAZOLE; ANTINEOPLASTIC AGENT; AROMATIC AMINE; ARYLAMINE N ACETYLTRANSFERASE 1; BENZOTHIAZOLE DERIVATIVE; CARCINOGEN; CISPLATIN; CJM 126; DRUG METABOLIZING ENZYME; ESTROGEN RECEPTOR; ETOPOSIDE; TAMOXIFEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; BREAST CANCER; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL GROWTH; DRUG DETOXIFICATION; DRUG DISTRIBUTION; DRUG RESISTANCE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ARYLAMINE N-ACETYLTRANSFERASE; BREAST NEOPLASMS; CARCINOGENS; HUMANS; ISOENZYMES; METABOLIC DETOXICATION, PHASE II;

EID: 77953489818     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791170905     Document Type: Article

References (69)

1. Hein D. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002; 65: 65-77.
2. Sim E, Walters K, Boukouvala S. Arylamine N-acetyltransferases: from structure to function. Drug Metab Rev 2008; 40: 479-510.
3. Rodrigues-Lima F, Dupret JM. In silico sequence analysis of arylamine N-acetyltransferases: evidence for an absence of lateral gene transfer from bacteria to vertebrates and first description of paralogs in bacteria. Biochem Biophys Res Commun 2002; 293: 783-92.
4. Martins M, Rodrigues-Lima F, Dairou J, et al. An acetyltransferase conferring tolerance to toxic aromatic amine chemicals: molecular and functional studies. J Biol Chem 2009; 284: 18726-33.
5. Matas N, Thygesen P, Stacey M, Risch A, Sim E. Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours. Cytogenet Cell Genet 1997; 77: 290-5.
6. Butcher N, Boukouvala S, Sim E, Minchin RF. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenom J 2002; 2: 30-42.
7. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1991; 39: 184-91.
8. Sim E, Westwood I, Fullam E. Arylamine N-acetyltransferases. Expert Opin Drug Metab Toxicol 2007; 3: 169-84.
9. Rodrigues-Lima F, Cooper R, Goudeau B, et al. Skeletal muscles express the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase. J Histochem Cytochem 2003; 51: 789-96.
10. Butcher NJ, Arulpragasam A, Goh HL, Davey T, Minchin RF. Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5'-UTR splice variants with altered translational activities. Biochem J 2005; 387: 119-27.
11. Husain A, Zhang X, Doll MA, States JC, Barker DF, Hein DW. Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab Dispos 2007; 35: 721-7.
12. Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000; 9: 29-42.
13. Sim E, Lack N, Wang CJ, et al. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology 2008; 254: 170-83.
14. Atmane N, Dairou J, Paul A, Dupret JM, Rodrigues-Lima F. Redox regulation of the human xenobiotic metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1). Reversible inactivation by hydrogen peroxide. J Biol Chem 2003; 278: 35086-92.
15. Dairou J, Atmane N, Dupret JM, Rodrigues-Lima F. Reversible inhibition of the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 by S-nitrosothiols. Biochem Biophys Res Commun 2003; 307: 1059-65.
16. Dairou J, Malecaze F, Dupret JM, Rodrigues-Lima F. The xenobiotic-metabolizing enzymes arylamine N-acetyltransferases (NAT) in human lens epithelial cells: inactivation by cellular oxidants and UVB-induced oxidative stress. Mol Pharmacol 2005; 67: 1299-306.
17. Butcher NJ, Arulpragasam A, Minchin RF. Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: a mechanism for the slow acetylator phenotype and substrate-dependent down-regulation. J Biol Chem 2004; 279: 22131-7.
18. Rodrigues-Lima F, Dairou J, Dupret JM. Effect of environmental substances on the activity of arylamine N-acetyltransferases. Curr Drug Metab 2008; 9: 505-9.
19. Evans DAP, White TA. Human acetylation polymorphism. J Lab Clin Med 1964; 63: 394-403.
20. Meisel P. Arylamine N-acetyltransferases and drug response. Pharmacogenomics 2002; 3: 349-66.
21. Minchin RF. Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells. Biochem J 1995; 307: 1-3.
22. Hein DW. N-Acetyltransferase genetics and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis. Toxicol Lett 2000; 112-113: 349-56.
23. Adam PJ, Berry J, Loader JA, et al. Arylamine N-Acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res 2003; 1: 826-35.
24. Bieche I, Girault I, Urbain E, Tozlu S, Lidereau R. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res 2004; 6: R252-63.
25. Wakefield L, Robinson J, Long H, et al. Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors. Genes Chromosomes Cancer 2008; 47: 118-26.
26. Russell AJ, Westwood IM, Crawford MH, et al. Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2. Bioorg Med Chem 2009; 17: 905-18.
27. Husain A, Barker DF, States JC, Doll MA, Hein DW. Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). Pharmacogenetics 2004; 14: 397-406.
28. Butcher NJ, Tiang J, Minchin RF. Regulation of arylamine N-acetyltransferases. Curr Drug Metab 2008; 9: 498-504.
29. Butcher NJ, Arulpragasam A, Pope C, Minchin RF. Identification of a minimal promoter sequence for the human N-acetyltransferase Type I gene that binds AP-1 (activator protein 1) and YY-1 (Yin and Yang 1). Biochem J 2003; 376: 441-8.
30. Barker DF, Husain A, Neale JR, et al. Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. Pharmacogenet Genomics 2006; 16: 515-25.
31. Wakefield L, Cornish V, Broackes-Carter F, Sim E. Arylamine N-acetyltransferase 2 expression in the developing heart. J Histochem Cytochem 2005; 53: 583-92.
32. Butcher NJ, Tetlow NL, Cheung C, Broadhurst GM, Minchin RF. Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. Cancer Res 2007; 67: 85-92.
33. Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 1993; 301: 71-6.
34. Boukouvala S, Fakis G. Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab Rev 2005; 37: 511-64.
35. Minchin RF, Hanna PE, Dupret JM, Wagner CR, Rodrigues-Lima F, Butcher NJ. Arylamine N-acetyltransferase I. Int J Biochem Cell Biol 2007; 39: 1999-2005.
36. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990; 9: 193-203.
37. Fretland AJ, Doll MA, Leff MA, Hein DW. Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1. Pharmacogenetics 2001; 11: 511-20.
38. Upton A, Johnson N, Sandy J, Sim E. Arylamine N-acetyltransferases - of mice, men and microorganisms. Trends Pharmacol Sci 2001; 22: 140-6.
39. Dhaini HR, Levy GN. Arylamine N-acetyltransferase 1 (NAT1) genotypes in a Lebanese population. Pharmacogenetics 2000; 10: 79-83.
40. Liu F, Zhang N, Zhou X, et al. Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation. J Mol Biol 2006; 361: 482-92.
41. Riddle B, Jencks WP. Acetyl-coenzyme A: arylamine N-acetyltransferase. Role of the acetyl- enzyme intermediate and the effects of substituents on the rate. J Biol Chem 1971; 246: 3250-8.
42. Dupret JM, Grant DM. Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2. J Biol Chem 1992; 267: 7381-5.
43. Sinclair JC, Sandy J, Delgoda R, Sim E, Noble ME. Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nat Struct Biol 2000; 7: 560-4.
44. Martins M, Pluvinage B, de la Sierra-Gallay IL, et al. Functional and structural characterization of the arylamine N-acetyltransferase from the opportunistic pathogen Nocardia farcinica. J Mol Biol 2008; 383: 549-60.
45. Wu H, Dombrovsky L, Tempel W, et al. Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases. J Biol Chem 2007; 282: 30189-97.
46. Rodrigues-Lima F, Deloménie C, Goodfellow GH, Grant DM, Dupret JM. Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: evidence for the conservation of a cysteine protease catalytic domain and an active- site loop. Biochem J 2001; 356: 327-34.
47. Mushtaq A, Payton M, Sim E. The C-terminus of arylamine N-acetyl transferase from Salmonella typhimurium controls enzymic activity. J Biol Chem 2002; 17: 12175-81.
48. Fullam E, Westwood IM, Anderton MC, Lowe ED, Sim E, Noble ME. Divergence of cofactor recognition across evolution: coenzyme A binding in a prokaryotic arylamine N-acetyltransferase. J Mol Biol 2008; 375: 178-91.
49. Liu L, Von Vett A, Zhang N, Walters KJ, Wagner CR, Hanna PE. Arylamine N-acetyltransferases: characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2. Chem Res Toxicol 2007; 20: 1300-8.
50. Kawamura A, Westwood I, Wakefield L, et al. Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransferase type 1. Biochem Pharmacol 2008; 75: 1550-60.
51. Cornish V, Pinter K, Boukouvala S, et al. Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene. Pharmacogenom J 2003; 3: 169-77.
52. Sugamori KS, Wong S, Gaedigk A, et al. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice. Mol Pharmacol 2003; 64: 170-9.
53. Wakefield L, Long H, Lack N, Sim E. Ocular defects associated with a null mutation in the mouse arylamine N-acetyltransferase 2 gene. Mamm Genome 2007; 18: 270-6.
54. Wakefield L, Cornish V, Long H, Griffiths WJ, Sim E. Deletion of a xenobiotic metabolizing gene in mice affects folate metabolism. Biochem Biophys Res Commun 2007; 364: 556-60.
55. Cao W, Chau B, Hunter R, Strnatka D, McQueen CA, Erickson RP. Only low levels of exogenous N-acetyltransferase can be achieved in transgenic mice. Pharmacogenom J 2005; 5: 255-61.
56. Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 2006; 25: 1649-58.
57. Agundez JA. Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab 2008; 9: 520-31.
58. Bradshaw TD, Chua MS, Orr S, Matthews CS, Stevens MF. Mechanisms of acquired resistance to 2-(4-aminophenyl)benzo- thiazole (CJM 126, NSC 34445). Br J Cancer 2000; 83: 270-7.
59. Thygesen P, Risch A, Stacey M, et al. Genes for human arylamine N-acetyltransferases in relation to loss of the short arm of chromosome 8 in bladder cancer. Pharmacogenetics 1999; 9: 1-8.
60. Kim SJ, Kang HS, Chang HL, et al. Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer. Oncol Rep 2008; 19: 663-8.
61. Lee JH, Lu HF, Wang DY, et al. Effects of tamoxifen on DNA adduct formation and arylamines N-acetyltransferase activity in human breast cancer cells. Res Commun Mol Pathol Pharmacol 2004; 115-116: 217-33.
62. Brooke GN, Parker MG, Bevan CL. Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene 2008; 27: 2941-50.
63. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101: 811-6.
64. Ott I, Gust R. Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. Anticancer Agents Med Chem 2007; 7: 95-110.
65. Ragunathan N, Dairou J, Pluvinage B, et al. Identification of the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) as a new target of cisplatin in breast cancer cells: molecular and cellular mechanisms of inhibition. Mol Pharmacol 2008; 73: 1761-8.
66. Malka F, Dairou J, Ragunathan N, Dupret JM, Rodrigues-Lima F. Mechanisms and kinetics of human arylamine N-acetyltransferase 1 inhibition by disulfiram. FEBS J 2009; 276: 4900-8.
67. Sauna ZE, Shukla S, Ambudkar SV. Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. Mol Biosyst 2005; 1: 127-34.
68. Brooke EW, Davies SG, Mulvaney AW, Pompeo F, Sim E, Vickers RJ. An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases. Bioorg Med Chem 2003; 11: 1227-34.
69. Madikane VE, Bhakta S, Russell AJ, et al. Inhibition of mycobacterial arylamine N-acetyltransferase contributes to anti- mycobacterial activity of Warburgia salutaris. Bioorg Med Chem 2007; 15: 3579-86.